Skip to content

Study · In vitro (cells) · 2015

3 results

Activation of AMP-activated protein kinase induce expression of FoxO1, FoxO3a, and myostatin after exercise-induced muscle damage.

Lee K, Ochi E, Song H, Nakazato K

Biochemical and biophysical research communications3 Sept 2015Cited by 29 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In L6 myotubes, AICAR showed a tendency toward increased FoxO1 phosphorylation similar to damaged gastrocnemius muscle.

    In plain wordsIn cells, AICAR showed a tendency toward increased FoxO1 phosphorylation, similar to damaged muscle.

    Outcome
    IncreaseFoxO1 phosphorylation
    Study

    n: not reported in source

    L6 myotubes
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    0.1, 0.5, 1, 1.5, and 2 mMAs given in this study.

    Source sentences

    Summary
    Furthermore, treatment of L6 myotubes with AICAR showed similar tendencies to that observed in in vivo gastrocnemius muscle treated with 180ECs.
    2 context sentences
    Summary · context
    The phosphorylated states of FoxO1, FoxO3a, and myostatin expression were increased significantly in response to 180ECs.
    Summary · context
    For evaluation of the direct relationships of AMPK and other proteins, we also examined contents of FoxOs and myostatin with stimulation of L6 myotube with AMPK agonist, 5 -aminoimidazole -4 -carboxamide -1-β-d-ribofuranoside (AICAR) (0.1, 0.5, 1, 1.5, and 2 mM).
  2. 02LabIn vitro (cells)Mechanism

    In L6 myotubes, AICAR showed a tendency toward increased FoxO3a phosphorylation similar to damaged gastrocnemius muscle.

    In plain wordsIn cells, AICAR showed a tendency toward increased FoxO3a phosphorylation, similar to damaged muscle.

    Outcome
    IncreaseFoxO3a phosphorylation
    Study

    n: not reported in source

    L6 myotubes
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    0.1, 0.5, 1, 1.5, and 2 mMAs given in this study.

    Source sentences

    Summary
    Furthermore, treatment of L6 myotubes with AICAR showed similar tendencies to that observed in in vivo gastrocnemius muscle treated with 180ECs.
    2 context sentences
    Summary · context
    The phosphorylated states of FoxO1, FoxO3a, and myostatin expression were increased significantly in response to 180ECs.
    Summary · context
    For evaluation of the direct relationships of AMPK and other proteins, we also examined contents of FoxOs and myostatin with stimulation of L6 myotube with AMPK agonist, 5 -aminoimidazole -4 -carboxamide -1-β-d-ribofuranoside (AICAR) (0.1, 0.5, 1, 1.5, and 2 mM).
  3. 03LabIn vitro (cells)Mechanism

    In L6 myotubes, AICAR showed a tendency toward increased myostatin expression similar to damaged gastrocnemius muscle.

    In plain wordsIn cells, AICAR showed a tendency toward increased myostatin expression, similar to damaged muscle.

    Outcome
    IncreaseMyostatin expression
    Study

    n: not reported in source

    L6 myotubes
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    0.1, 0.5, 1, 1.5, and 2 mMAs given in this study.

    Source sentences

    Summary
    Furthermore, treatment of L6 myotubes with AICAR showed similar tendencies to that observed in in vivo gastrocnemius muscle treated with 180ECs.
    2 context sentences
    Summary · context
    The phosphorylated states of FoxO1, FoxO3a, and myostatin expression were increased significantly in response to 180ECs.
    Summary · context
    For evaluation of the direct relationships of AMPK and other proteins, we also examined contents of FoxOs and myostatin with stimulation of L6 myotube with AMPK agonist, 5 -aminoimidazole -4 -carboxamide -1-β-d-ribofuranoside (AICAR) (0.1, 0.5, 1, 1.5, and 2 mM).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.